Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients With Sickle Cell Disease Aged 6 to <12 years: 2-Year Data From the Phase 2 Solace-Kids Study

Oral Presentation
© 2024 American Society of Hematology. All rights reserved.
Meeting: 2024 ASH® Annual Meeting
Indication: Sickle Cell Disease (SCD)
Presenter: Matthew M. Heeney, MD
Affiliation: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA
Presentation Date: December 7, 2024
Abstract Number: 180
Session: Session: 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Therapeutic Advances in Sickle Cell Disease

To access this content please accept the following declarations.

This content was selected by and is provided to you upon your unsolicited request courtesy of Novartis with permission of ASH®.